Rabeprazole

Rabeprazole /ˌræ.ˈbɛp.ræ.zɔːl/ is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co.and is marketed by Janssen-Cilag as the sodium salt under the brand names AcipHex (/ˈæsɨfɛks/, referring to pH) in the US, Pariet in Europe, Brazil, Canada, Japan, Russia and Australia. Rabonik in India, and Zechin in Pakistan. In Bangladesh Rabeprazole is sold under the brand name of Acifix by Beximco Pharma.

Indications and usage[edit]

Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.

• Gastric ulcer (GU)
• Peptic ulcer disease (PUD)
• Maintenance of healing of erosive or ulcerative GERD
• Healing of erosive and ulcerative GERD
• Healing of duodenal ulcers.
• Treatment of symptomatic GERD
• Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
• Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence

Contraindications[edit]

• hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
• lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.

Restriction of usage[edit]

• acute liver failure
• pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)